ArticleWomen's health (London, England)
Implementation considerations for long-acting injectable PrEP rollout among female sex workers in South Africa: A qualitative analysis guided by the Consolidated Framework for Implementation Research.
Article in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
BackgroundFemale sex workers (FSW) in South Africa are disproportionately impacted by HIV, yet daily oral pre-exposure prophylaxis (PrEP) initiation and continuation rates among FSW remain low. Long-acting injectable PrEP (LAI-PrEP) may alleviate many oral PrEP adherence challenges; however, LAI-PrEP remains largely unavailable in South Africa.ObjectivesExplore the multilevel contextual determinants likely to influence LAI-PrEP's implementation among FSW to inform rollout strategies.DesignCross-sectional, qualitative study with in-depth interviews and focus group discussions.MethodsFrom May to June 2024, 42 adult FSW not living with HIV and accessing services from two decentralized FSW delivery sites in eThekwini and Ehlanzeni participated in interviews (12 per study site; n=24 FSW total) and focus groups (1 per study site; n=18 FSW total). Four providers were also interviewed (2 per study site). Semi-structured guides, based on the Consolidated Framework for Implementation Research (CFIR), elicited client and provider perceptions of contextual factors hypothesized to influence future LAI-PrEP implementation, mapped to CFIR constructs through team-based, deductive thematic analysis.ResultsMany FSW conveyed strong acceptance and preferences for LAI-PrEP due to perceived advantages over oral PrEP including greater dosing privacy in clinical spaces, fewer dispensing intervals, and reduced stress from daily pill-taking. Providers perceived LAI-PrEP as a priority to augment existing HIV prevention services; however, financial investments, additional staff, and LAI-PrEP counseling training would be needed to enhance programmatic capabilities. Prioritization of non-discriminatory provider attitudes will be crucial to combat persistent racialized and economic inequities that exacerbate stigma against FSW in public healthcare facilities. Finally, decentralized delivery, utilizing community champions, and integrating LAI-PrEP with other health services emerged as promising strategies to ensure an equitable rollout of LAI-PrEP, assuming adequate global or national investment.ConclusionFindings suggest that LAI-PrEP is perceived by both potential recipients and deliverers to effectively address several barriers to oral PrEP continuation, making it a promising advancement in the landscape of HIV prevention. Implementation strategies that integrate identified stakeholder priorities and preferences, anticipated barriers, and existing programmatic strengths, will likely optimize LAI-PrEP rollout among a historically marginalized population in South Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.